Impact of Fas/Fasl Gene Polymorphisms on Susceptibility Risk and Imatinib Mesylate Treatment Response in Chronic Myeloid Leukaemia Patients.

Aziati Azwari AnnuarRavindran AnkathilNazihah Mohd YunusAzlan HusinNur Shafawati Ab RajabAhmad Aizat Abdul Aziz Mohd Ismail Ibrahim Sarina Sulong

Published in: Asian Pacific journal of cancer prevention : APJCP (2021)

The genetic polymorphism FASL-844 T>C may contribute to the CML susceptibility risk and also IM treatment response in CML patients. Accodringly, it may be useful as a biomarker for predicting CML susceptibility risk and IM resistance.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
chronic myeloid leukemia
prognostic factors
peritoneal dialysis
bone marrow